A Phase 2 Study of Cabozantinib in People With Meningioma

Full Title

Purpose

Researchers want to see how well cabozantinib works to treat meningioma, a type of brain tumor. The people in this study have meningiomas that came back or keep growing even after treatment.

Cabozantinib is already used to treat other types of cancer. It is a tyrosine kinase inhibitor (TKI). TKIs are drugs that block the action of enzymes called tyrosine kinases. Tyrosine kinases may be too active or found at high levels in some types of cancer cells.

By blocking these enzymes, cabozantinib may help slow or stop the growth of your cancer. This drug is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have meningioma that came back or keeps growing after treatment.
• Have finished prior treatment at least 4 weeks before taking cabozantinib.
• Have completed prior surgery or radiation therapy at least 6 months before entering the study.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Thomas Kaley’s office at 212-639-5122.